On Monday, Aimmune Therapeutics announced that it had agreed to Nestle’s $2 billion dollar acquisition. Yahoo Finance’s Anjalee Khemlani sat down with Jayson Dallas, Aimmune’s CEO, to speak about the acquisition and about the peanut allergy treatment development.
January 29, 2021
January 30, 2021
November 3, 2020
Every Coronavirus Vaccine Deal Novavax Has NegotiatedSeptember 1, 2020